Ipsen and Medicis announce submission of Reloxin(R) BLA in aesthetics to the FDA

Regulatory News:

Medicis (NYSE: MRX) and Ipsen (Euronext: IPN) today announced that
Ipsen has submitted a Biologics License Application ("BLA") for the
botulinum toxin type A, Reloxin(R)(1), in aesthetic indications
(glabellar lines) to the U.S. Food and Drug Administration´s ("FDA")
Division of Dermatology and Dental Products, within the Center for
Drug Evaluation and Research. This BLA submission by Ipsen is intended
to address the concerns cited by the FDA when it declined to file the
Reloxin(R) BLA in January 2008, which Medicis had submitted in late
2007. Standard response timeframe from the FDA is expected
approximately 10 months following receipt of the Reloxin(R)
submission. Subject to approval of the BLA by the FDA, Medicis intends
to commercialize Reloxin(R) in the U.S. in accordance with the
long-standing arrangement between Medicis and Ipsen. Changes from the
original BLA submission relate primarily to sponsorship and ownership
of the filing. The substantive elements of the original submission
remain unchanged.

Jean-Luc Belingard, Chairman and Chief Executive Officer of Ipsen,
said: "We are pleased to have responded to the administrative issues
raised by the FDA in coordination with Medicis in a timely and
efficient manner. Together with Medicis, we look forward to working
diligently with the FDA to obtain a successful marketing approval.
Given Ipsen´s botulinum toxin positive track record on a global basis,
we look forward to entering the North American market following FDA
approval of Reloxin(R)."

"We are pleased to announce this submission of the BLA for
Reloxin(R) in aesthetics with FDA," said Jonah Shacknai, Chairman and
Chief Executive Officer of Medicis. "Both the Ipsen and Medicis teams
have worked diligently with FDA to determine the best solution for
submitting Reloxin(R) in aesthetics. We thank everyone involved, and
extend our appreciation to FDA for its willingness to work with us on
a resolution in a timely fashion. We continue to believe the
Reloxin(R) BLA is strong, and anticipate entering in the growing,
multi-million dollar aesthetic botulinum toxin market in the U.S. upon
FDA approval."

In March 2006, Ipsen granted Medicis the rights to develop,
distribute and commercialize Ipsen´s botulinum toxin product in the
United States, Canada and Japan for aesthetic use by physicians. Upon
FDA´s acceptance of the Reloxin(R) submission, Medicis will pay Ipsen
approximately $25 million in accordance with the agreement between the
parties.

According to the American Society for Aesthetic Plastic Surgery,
injections of botulinum toxin type A were the number one non-surgical
procedure in 2006, with over 3 million total procedures. Current
growth estimates in botulinum toxin type A in dollars are estimated to
be in excess of 20 percent over the prior year. This translates into a
retail U.S. aesthetic market of approximately $300 million-$400
million.(2)

About Ipsen´s Botulinum Toxin Type A

As of October 2007, Ipsen´s botulinum toxin type A is approved for
aesthetic indications in 21 countries: Argentina, Australia, Belarus,
Brazil, Columbia, Ecuador, Egypt, Germany, Honduras, Israel,
Kazakhstan, Mexico, Moldova, New Zealand, Philippines, Slovak
Republic, Ukraine, Uruguay, Venezuela, Vietnam, and Russia (in Russia,
it is the first botulinum toxin type A approved in this field). Ipsen
is also pursuing regulatory approval for medical indications for the
product in certain additional key international markets.

Dysport(R) is a neuromuscular blocking toxin which acts to block
acetylcholine release, hence reducing muscular spasm and was initially
developed for the treatment of motor disorders and various forms of
muscular spasticity, including cervical dystonia (a chronic condition
in which the neck is twisted or deviated), spasticity of the lower
limbs (heal) in children with cerebral palsy, blepharospasm
(involuntary eye closure) and hemifacial spasm. It was later developed
for the treatment of a wide variety of neuromuscular disorders and
aesthetic medicine. Dysport(R) was originally launched in the United
Kingdom in 1991 and has marketing authorisations in over 70 countries
(at 31 December 2006). Ipsen has just recently filed a BLA for
Dysport(R) in cervical dystonia to the FDA.

About Ipsen

Ipsen is a European pharmaceutical group with over 20 products on
the market and a total worldwide staff of nearly 4,000. The company´s
development strategy is based on a combination of products in targeted
therapeutic areas (oncology, endocrinology and neuromuscular
disorders) which are growth drivers, and primary care products which
contribute significantly to its research financing. This strategy is
also supported by an active policy of partnerships. The location of
its four R&D centres (Paris, Boston, Barcelona, London) gives the
Group a competitive edge in gaining access to leading university
research teams and highly qualified personnel. In 2007, Research and
Development expenditure was EUR 185 million, in excess of 20% of
consolidated sales, which amounted to EUR 920.5 million while total
revenues amounted to EUR 993.8 million (in IFRS). More than 700 people
in Research & Development are dedicated to the discovery and
development of innovative drugs for patient care. Ipsen´s shares are
traded on Segment A of Eurolist by Euronext(TM) (stock code: IPN, ISIN
code: FR0010259150). Ipsen´s shares are eligible to the "Service de
Reglement Differe" ("SRD") and the Group is part of the SBF 120 index.
For more information on Ipsen, visit our website at www.ipsen.com.

Ipsen Forward-looking statements

The forward-looking statements and targets contained herein are
based on Ipsen´s management´s current views and assumptions. Such
statements involve known and unknown risks and uncertainties that may
cause actual results, performance or events to differ materially from
those anticipated herein. The targets contained herein were prepared
without taking into account external growth assumptions, which may
alter the parameters. These targets are based on data and assumptions
regarded as reasonable by the Group and depend on conditions or facts
likely to happen in the future, and not exclusively on historical
data. Actual results may depart significantly from the targets given
the occurrence of certain risks and uncertainties. The Group does not
commit nor gives any guarantee that it will meet the targets mentioned
above. Moreover, the Research and Development process involves several
stages at each of which there is a substantial risk that the Group
will fail to achieve its objectives and be forced to abandon its
efforts in respect of a product in which it has invested significant
sums. Therefore, the Group cannot be certain that favourable results
obtained during pre-clinical trials will be confirmed subsequently
during clinical trials, or that the results of clinical trials will be
sufficient to demonstrate the safe and effective nature of the product
concerned. Moreover, the targets described in this document were
prepared without taking into account external growth assumptions,
which may alter these parameters. These targets are based on data and
assumptions regarded as reasonable by the Group. These targets depend
on conditions or facts likely to happen in the future, and not
exclusively on historical data. Actual results may depart
significantly from these targets given the occurrence of certain risks
and uncertainties. The Group does not commit nor gives any guarantee
that it will meet the targets mentioned above. Ipsen expressly
disclaims any obligation or undertaking to update or revise any
forward looking statements, targets or estimates contained in this
press release to reflect any change in events, conditions, assumptions
or circumstances on which any such statements are based, unless so
required by applicable law. Ipsen´s business is subject to the risk
factors outlined in its information documents filed with the French
Autorite des Marches Financiers.

About Medicis

Medicis is the leading independent specialty pharmaceutical
company in the United States focusing primarily on the treatment of
dermatological and aesthetic conditions. The Company is dedicated to
helping patients attain a healthy and youthful appearance and
self-image. Medicis has leading branded prescription products in a
number of therapeutic and aesthetic categories. The Company´s products
have earned wide acceptance by both physicians and patients due to
their clinical effectiveness, high quality and cosmetic elegance.The
Company´s products include the prescription brands RESTYLANE(R)
(hyaluronic acid), PERLANE(R) (hyaluronic acid), DYNACIN(R)
(minocycline HCl), LOPROX(R) (ciclopirox), PLEXION(R) (sodium
sulfacetamide/sulfur), SOLODYN(R) (minocycline HCl, USP) Extended
Release Tablets, TRIAZ(R) (benzoyl peroxide), LIDEX(R) (fluocinonide)
Cream, 0.05%, VANOS(R) (fluocinonide) Cream, 0.1%, and ZIANA(R)
(clindamycin phosphate 1.2% and tretinoin 0.025%) Gel, BUPHENYL(R)
(sodium phenylbutyrate) and AMMONUL(R) (sodium phenylacetate/sodium
benzoate), prescription products indicated in the treatment of Urea
Cycle Disorder, and the over-the-counter brand ESOTERICA(R). For more
information about Medicis, please visit the Company´s website at
www.medicis.com.

Medicis Forward-Looking Statements

This press release contains "forward-looking statements" within
the meaning of the Private Securities Litigation Reform Act. All
statements included in this press release that address activities,
events or developments that Medicis expects, believes or anticipates
will or may occur in the future are forward-looking statements,
including FDA´s acceptance of the Reloxin(R) submission, the timing
associated with FDA´s response to the submission and the potential
commercialization of Reloxin(R). These statements are based on certain
assumptions made by Medicis based on its experience and perception of
historical trends, current conditions, expected future developments
and other factors it believes are appropriate in the circumstances. No
assurances can be given, however, that these activities, events or
developments will occur or that such results will be achieved. Such
statements are subject to a number of assumptions, risks and
uncertainties, many of which are beyond the control of Medicis.
Several of these risks are outlined in the Company´s most recent
annual report on Form 10-K for the year ended December 31, 2007, and
other documents we file with the Securities and Exchange Commission.
Forward-looking statements represent the judgment of Medicis´
management as of the date of this release, and Medicis disclaims any
intent or obligation to update any forward-looking statements
contained herein, which speak as of the date hereof.

NOTE: Full prescribing information for any Medicis prescription
product is available by contacting the Company. RESTYLANE(R) and
PERLANE(R) are trademarks of HA North American Sales AB, a subsidiary
of Medicis Pharmaceutical Corporation. All other marks are the
property of Medicis or its affiliates.

(1) The proposed name for the product in the U.S. aesthetic market
is Reloxin(R), and it is called Dysport(R) for medical and aesthetic
markets outside the U.S.

(2) American Society for Aesthetic Plastic Surgery, Cosmetic
Surgery National Data Bank Statistics, 2006 and Allergan company
reports